Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models.

Pyry Antti Juhana Välitalo
Author Information
  1. Pyry Antti Juhana Välitalo: School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210, Kuopio, Finland. pyry.valitalo@gmail.com.

Abstract

Lack of data is an obvious limitation to what can be modelled. However, aggregate data in the form of means and possibly (co)variances, as well as previously published pharmacometric models, are often available. Being able to use all available data is desirable, and therefore this paper will outline several methods for using aggregate data as the basis of parameter estimation. The presented methods can be used for estimation of parameters from aggregate data, and as a computationally efficient alternative for the stochastic simulation and estimation procedure. They also allow for population PK/PD optimal design in the case when the data-generating model is different from the data-analytic model, a scenario for which no solutions have previously been available. Mathematical analysis and computational results confirm that the aggregate-data FO algorithm converges to the same estimates as the individual-data FO and yields near-identical standard errors when used in optimal design. The aggregate-data MC algorithm will asymptotically converge to the exactly correct parameter estimates if the data-generating model is the same as the data-analytic model. The performance of the aggregate-data methods were also compared to stochastic simulations and estimations (SSEs) when the data-generating model is different from the data-analytic model. The aggregate-data FO optimal design correctly predicted the sampling distributions of 200 models fitted to simulated datasets with the individual-data FO method.

Keywords

References

  1. CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):621-633 [PMID: 31207186]
  2. Clin Pharmacokinet. 2013 Jan;52(1):43-57 [PMID: 23212609]
  3. J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79 [PMID: 925881]
  4. J Biopharm Stat. 2003 May;13(2):209-27 [PMID: 12729390]
  5. J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):575-93 [PMID: 17620001]
  6. Comput Methods Programs Biomed. 2001 May;65(2):141-51 [PMID: 11275334]
  7. Comput Methods Programs Biomed. 2004 Apr;74(1):29-46 [PMID: 14992824]
  8. Biostatistics. 2016 Oct;17(4):737-50 [PMID: 27166250]
  9. Br J Clin Pharmacol. 2015 Sep;80(3):534-47 [PMID: 26095234]
  10. J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51 [PMID: 7334463]
  11. J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):635-59 [PMID: 19130188]
  12. J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19 [PMID: 6644555]
  13. Br J Clin Pharmacol. 2015 Jan;79(1):6-17 [PMID: 24548174]
  14. J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71 [PMID: 7229908]
  15. Ann Biomed Eng. 2003 Jan;31(1):98-111 [PMID: 12572660]

MeSH Term

Algorithms
Computer Simulation
Data Interpretation, Statistical
Humans
Models, Statistical
Pharmacokinetics

Word Cloud

Created with Highcharts 10.0.0datamodelaggregatemethodsestimationaggregate-dataFOmodelsavailableoptimaldesigndata-generatingdata-analyticcanpreviouslypharmacometricwillparameterusedstochasticalsodifferentalgorithmestimatesindividual-datasimulatedLackobviouslimitationmodelledHoweverformmeanspossiblycovarianceswellpublishedoftenableusedesirablethereforepaperoutlineseveralusingbasispresentedparameterscomputationallyefficientalternativesimulationprocedureallowpopulationPK/PDcasescenariosolutionsMathematicalanalysiscomputationalresultsconfirmconvergesyieldsnear-identicalstandarderrorsMCasymptoticallyconvergeexactlycorrectperformancecomparedsimulationsestimationsSSEscorrectlypredictedsamplingdistributions200fitteddatasetsmethodPharmacometricincludingAggregateModel-basedmeta-analysisPharmacometricsPopulationpharmacokinetics

Similar Articles

Cited By (1)